Diabetes: Selective FOXO1 modulation
Nature Reviews Drug Discovery 16, 828 (2017).
doi:10.1038/nrd.2017.235
Author: Sarah Crunkhorn
Inhibition of the FOXO1 transcription factor has beneficial effects on diabetic hyperglycaemia through the suppression of glucose-6-phosphatase (G6PC) activation, but it also suppresses glucokinase (GCK) inhibition, which promotes lipogenesis. Here, Langlet et al. identify SIN3A as the corepressor required for FOXO1-mediated inhibition of GCK.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research